Cadila gets USFDA nod for depression tab Risperidone
Mumbai, Oct 20 : Pharmaceutical company Cadila Healthcare today said that its parent firm Zydus Cadila has received US Food and Drug Administration (USFDA) approval to market Risperidone Tablets, used to treat depression.
Risperidone falls in the central nervous system (CNS) segment, Cadila Healthcare stated in a filing to the Bombay Stock Exchange.
The group now has 41 approvals and has so far filed for 79 Abbreviated New Drug Application's (ANDA), it added.
Last week, Zydus Cadila filed an Investigational New Drug application with the Drugs Controller General of India for ZYT 1, which is used to prevent heart attack and stroke.
Shares of the Company were trading at Rs 258, down 2.69 per cent in the noon session on the Bombay Stock Exchange.
October 29, 2008